EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #07174_C
cGMP，无酶细胞解离试剂
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。
总览
使用 Gentle Cell Dissociation Reagent（GCDR）可将人胚胎干细胞（ES）或人诱导多能干细胞（iPS）解离成细胞聚集体，以便常规传代，或解离成单细胞悬液。这款无酶且化学成分明确的试剂可确保人ES和iPS细胞在常规培养过程中实现高扩增。它还适用于分离肠隐窝以建立肠类器官，以及在类器官培传代培养过程中分解 Corning® Matrigel® 穹顶结构。
CDR 现已按照相关的cGMP标准、在认证的质量管理体系下生产，确保产品质量一致、结果可重复。
如需申请 Gentle Cell Dissociation Reagent 药物主文件（DMF）的授权书（LOA），请点击此处。
分类
非酶法
细胞类型
内胚层，PSC衍生，肠道细胞，多能干细胞
种属
人，小鼠
应用
细胞培养
研究领域
上皮细胞研究，干细胞生物学
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (9)
文献 (17)
Simple suspension culture system of human iPS cells maintaining their pluripotency for cardiac cell sheet engineering.
Journal of Tissue Engineering and Regenerative Medicine 2015 DEC
Abstract
In this study,a simple three-dimensional (3D) suspension culture method for the expansion and cardiac differentiation of human induced pluripotent stem cells (hiPSCs) is reported. The culture methods were easily adapted from two-dimensional (2D) to 3D culture without any additional manipulations. When hiPSCs were directly applied to 3D culture from 2D in a single-cell suspension,only a few aggregated cells were observed. However,after 3 days,culture of the small hiPSC aggregates in a spinner flask at the optimal agitation rate created aggregates which were capable of cell passages from the single-cell suspension. Cell numbers increased to approximately 10-fold after 12 days of culture. The undifferentiated state of expanded hiPSCs was confirmed by flow cytometry,immunocytochemistry and quantitative RT-PCR,and the hiPSCs differentiated into three germ layers. When the hiPSCs were subsequently cultured in a flask using cardiac differentiation medium,expression of cardiac cell-specific genes and beating cardiomyocytes were observed. Furthermore,the culture of hiPSCs on Matrigel-coated dishes with serum-free medium containing activin A,BMP4 and FGF-2 enabled it to generate robust spontaneous beating cardiomyocytes and these cells expressed several cardiac cell-related genes,including HCN4,MLC-2a and MLC-2v. This suggests that the expanded hiPSCs might maintain the potential to differentiate into several types of cardiomyocytes,including pacemakers. Moreover,when cardiac cell sheets were fabricated using differentiated cardiomyocytes,they beat spontaneously and synchronously,indicating electrically communicative tissue. This simple culture system might enable the generation of sufficient amounts of beating cardiomyocytes for use in cardiac regenerative medicine and tissue engineering.
A systematic evaluation of integration free reprogramming methods for deriving clinically relevant patient specific induced pluripotent stem (iPS) cells
PLoS ONE 2013 NOV
Abstract
A systematic evaluation of three different methods for generating induced pluripotent stem (iPS) cells was performed using the same set of parental cells in our quest to develop a feeder independent and xeno-free method for somatic cell reprogramming that could be transferred into a GMP environment. When using the BJ fibroblast cell line,the highest reprogramming efficiency (1.89% of starting cells) was observed with the mRNA based method which was almost 20 fold higher than that observed with the retrovirus (0.2%) and episomal plasmid (0.10%) methods. Standard characterisation tests did not reveal any differences in an array of pluripotency markers between the iPS lines derived using the various methods. However,when the same methods were used to reprogram three different primary fibroblasts lines,two derived from patients with rapid onset parkinsonism dystonia and one from an elderly healthy volunteer,we consistently observed higher reprogramming efficiencies with the episomal plasmid method,which was 4 fold higher when compared to the retroviral method and over 50 fold higher than the mRNA method. Additionally,with the plasmid reprogramming protocol,recombinant vitronectin and synthemax® could be used together with commercially available,fully defined,xeno-free essential 8 medium without significantly impacting the reprogramming efficiency. To demonstrate the robustness of this protocol,we reprogrammed a further 2 primary patient cell lines,one with retinosa pigmentosa and the other with Parkinsons disease. We believe that we have optimised a simple and reproducible method which could be used as a starting point for developing GMP protocols,a prerequisite for generating clinically relevant patient specific iPS cells.
Deriving functional hepatocytes from pluripotent stem cells.
Current protocols in stem cell biology 2014
Abstract
Despite major progress in the management of human liver disease,the only cure for a critically failing organ is liver transplantation. While a highly successful approach,the use of cadaveric organs as a routine treatment option is severely limited by organ availability. Therefore,the use of cell-based therapies has been explored to provide support for the failing liver. In addition to developing new treatments,there is also an imperative to develop better human models 'in a dish'. Such approaches will undoubtedly lead to a better understanding of the disease process,offering new treatment or preventative strategies. With both approaches in mind,we have developed robust hepatocyte differentiation methodologies for use with pluripotent stem cells. Importantly,our procedure is highly efficient (∼ 90%) and delivers active,drug-inducible,and predictive human hepatocyte populations.
更多信息
| 物种 | 人, 小鼠 |
|---|
相关产品
-
STEMdiff™定型内胚层检测试剂盒<p>用于将人胚胎干细胞（hESCs）和人诱导多能干细胞（iPSCs）分化为确定性内胚层的定义明确、无动物源成分的培养基</p>
-
STEMdiff™ 神经诱导培养基用于人 ES 和 iPS 细胞神经诱导的成分明确的无血清培养基
-
IntestiCult™ 类器官生长培养基 (小鼠)用于建立和维持小鼠肠道类器官的培养基
-
mTeSR™ PluscGMP，稳定无饲养层维持培养基，适用于人ES和iPS 细胞
THIS PRODUCT IS MANUFACTURED AND TESTED FOLLOWING RELEVANT CGMPs UNDER A CERTIFIED QUALITY MANAGEMENT SYSTEM. PRODUCT IS FOR FURTHER MANUFACTURING OR RESEARCH USE. NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. 欲获悉更多关于STEMCELL的质控信息，请访问 WWW.STEMCELL.COM/COMPLIANCE
沪公网安备31010102008431号
在线联系